Semaglutide — Indexed Studies

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Meyhöfer SM, Cariou B, Cercato C et al.

Effect of Semaglutide on Body Weight, Blood Lipid Profile, and Adipokine Status in Obese Patients.

Tyurina AV, Kurochkina NS, Yezhov MV

Peripheral Eosinophilia in a Patient With Subacute Watery Diarrhea.

Roldan GA, Dapke K, Reinink A

Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity.

Wu JY, Lin YM, Hsu WH et al.

Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction.

Ohkuma T, Aotani R, Sakamoto W et al.

Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study.

Moreno-Pérez Ó, Tejera-Muñoz A, Leiva-Mora N et al.

Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Gao W, Cai X, Wang X et al.

GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.

Musa EYA, Musa AYA

Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide.

Barenbaum SR, Gonzalez A, Verzani Z et al.

Altered Mental Status Due to Amantadine Withdrawal: A Case Report.

Asal NJ, Piraino E, Hamacher C et al.

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.

Nanna MG, Mena-Hurtado C, Divino V et al.

Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study).

Kapoor N, Kalra S, Naskar A et al.

Readability and understandability of online patient education on semaglutide.

Wilson AQ, Chamberlin SM, Dabbs WS et al.

Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real-World Evidence From the REALISED Study.

Wannachalee T, Anthanont P, Sirisreetreerux S et al.

Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.

Yang SI, Kim SW, Son KH et al.

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.

Cummings JL, Atri A, Sano M et al.

Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.

Sebastian SA, Ayyalu T, Bimal T et al.

Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors on Atherosclerotic Cardiovascular Risk Among Patients With Type 2 Diabetes in Primary Health Care Settings in Jeddah, Saudi Arabia.

A Ljohani R, Aldubi R, Bagabas I et al.

First Experience With Semaglutide for the Treatment of Obesity in Nondiabetic Patient With Progressive Dysfunction of Renal Graft.

Miertová Z, Blichová T, Vnučák M et al.

A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus.

Joshi S, Das AK, Khunti K et al.

Semaglutide in patients with hidradenitis suppurativa and obesity.

Nicolau J, Sanchís P, Nadal A et al.

Very low energy ketogenic diet vs. Mediterranean diet for MASLD: Superior steatosis reduction in a randomised pilot study.

Farrell AM, Paris T, Parr EB et al.

Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon-Like Peptide 1 Agonist: A Case Report.

Kumar S, Cobb R, Matson A et al.

Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.

Ciudin A, Sapin H, Fan L et al.

A case of type 2 diabetes with spinal and bulbar muscular atrophy treated with oral semaglutide while sparing muscle reduction for two years: a case report with literature review.

Nakano Y, Morita S, Nishi N et al.

Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions.

Mondoh A, Contreras F, Craig H et al.

Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications.

Gougol A, Kwo P, Pike W et al.

Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes.

Akturk HK, Mason E, Cengiz D et al.

Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing’s syndrome: a multicenter retrospective study.

Iglesias P, Nobre EL, Hanzu F et al.

Beyond Patient Factors: Are we Missing the Surgical Context in Comparing Tirzepatide and Semaglutide Post-CABG?

Chen M, Han Y, Zhang F

The Risk of Aspiration Is Low With Continuing Semaglutide During Elective Eye Surgery When Patients Receive Only Moderate Sedation.

Zapp C, Downer Ii DM, Levine A et al.

Simultaneous bilateral NAION following initiation of high-dose semaglutide: a case report.

Asensio-Sánchez VM, Rodríguez-Espinosa J, Silva-Schultz S et al.

Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gaps.

Gaytan G, Pabon A, Rosario N

Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.

Ganeshalingam AA, Uhrenholt N, Arnfred S et al.

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.

Heymsfield SB, Aronne LJ, Montgomery P et al.

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.

Kanumilli N, Osumili B, Evans J et al.

Investigating the Link Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Non-arteritic Ischemic Optic Neuropathy: A Case Report of Semaglutide-Induced Optic Neuropathy.

Bakheet M, Chaudhary A

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.

Rosenstock J, Yabe D, Cox D et al.

New weight loss pill outperforms oral semaglutide for diabetes patients, study reports.

Wise J

RETRACTION: Comparative efficacy of semaglutide versus liraglutide on weight loss and glycaemic control.

Ullah H, Khan ZU, Wazir A et al.

FDA Approves Higher-Dose Injectable Semaglutide.

Anderer S

Sex-specific metabolic responses to glucagon receptor agonism and modulation of the FGF21-glucagon axis in female mice.

Merrild C, Johansen VBI, Clemmensen C et al.

Preoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes in Orthopaedic Surgery: A Scoping Review of Perioperative and Recovery Outcomes.

Strickler I, Jensen A, Cragg K et al.

Semaglutide as a potential tool in pre-lung transplant weight loss optimization.

Ali R, Keyt H, Solis-Herrera C et al.

Medicare Spending Implications for Semaglutide Under Voluntary Price Agreements.

Dusetzina SB, Castle G, Han J et al.

Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss.

Bozadjieva-Kramer N, McMahon G, Li Z et al.

Responses to GLP-1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data.

Mallette JH, Speed JS, Lirette ST et al.

Er-Chen Decoction ameliorates metabolic dysfunction-associated steatotic liver disease via gut microbiota-barrier axis-driven hepatic metabolic reprogramming.

Yang K, Huang Y, Gu L et al.

Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass.

Castelletto V, de Mello LR, Seitsonen J et al.

Semaglutide for obesity: a pill for every ill?

Puntis JW